CT company wins up to $9.4M contract for Anthrax testing tech

BY John Stearns

Branford's Tangen Biosciences has won a federal contract valued at up to $9.4 million to develop an Anthrax diagnostic test.

The contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) will advance the ability to combat the threat of Anthrax, a potentially deadly bacteria that can cause skin, lung and other diseases, by utilizing Tangen's TangenDx Molecular Diagnostic System. The system is a rapid and fully portable diagnostic platform.

Speed is key for earlier and more accurate diagnosis of the deadly infection in blood samples, allowing for more effective treatment and improved tracking of outbreaks, Tangen said.

The contract with BARDA will fund the development and commercialization of Tangen's diagnostic technology.

The three-phase, 3.5-year project is expected to result in an FDA submission for clearance of the Anthrax test. Phase one of the contract, which began in October, is valued at $3.2 million, followed by two optional phases valued at an additional $6.2 million.